Viking's Obesity Edge May Be Staying Power, Not Weight Loss

Key Points

• Viking Therapeutics shares jumped 36% after new data showed patients on VK2735 kept most weight loss when switched to less frequent dosing.
• The maintenance edge could differentiate Viking from Eli Lilly and Novo Nordisk, though rivals Amgen and Pfizer are also pursuing monthly dosing options.
• Phase 3 VANQUISH trial readouts are expected in 2027, and Viking's roughly $502 million in cash may not cover a full commercial launch.

Viking Therapeutics NASDAQ: VKTX stock jumped 36% on Sept. 22. The catalyst was new maintenance data for VK2735, its GLP-1/GIP obesity candidate, which showed that patients maintained most of their weight loss after switching from weekly shots to every-other-week or monthly dosing.

Investors shouldn't oversimplify this to just another win in the obesity drug market. This study wasn't about how much weight patients lose. It was about how long they keep it off, and how often they need a shot to do it.

That distinction matters because the GLP-1 market is maturing. The category is crowded, and pricing is under pressure. Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO are fighting hardest over peak weight loss. Competing on that data point alone is a losing game for a clinical-stage company.

Viking may be able to take a different path. An edge in weight-loss maintenance means Viking's candidate offers an additional benefit beyond just being "a cheaper Zepbound." That presents a question to investors. Is less frequent dosing a real commercial edge, or is it just a nice feature in a market where Lilly already dominates?

What the VK2735 Data Actually Show

Roughly 180 adults with obesity took a weekly dose of VK2735 or a placebo for 21 weeks. Weight loss ranged from about 16% to 19%, versus roughly 0% for the placebo. Patients were then moved to less frequent dosing for 12 weeks.

Viking's headline numbers showed patients maintained weight loss at rates of 97% and 90%. But investors need to look at the details. Each comes from a single dose group of about a dozen patients.

The combined averages tell a cleaner story. Patients switched to every other week dosing kept 90% of their weight loss. Monthly patients kept 85%. Those moved to placebo kept 61%. Gastrointestinal side effects during maintenance were similar to placebo.

Is Less Frequent Dosing a Real Edge?

The current best-selling GLP-1 drugs are weekly injections. Lilly's Zepbound and Novo's Wegovy both require a shot every week. Both companies now also sell daily pills. Novo's Wegovy pill was approved in December, and Lilly's Foundayo followed in April.

Lilly has already staked a claim on maintenance. In its ATTAIN-MAINTAIN trial, patients switched from Wegovy to daily orforglipron. Over 52 weeks, they kept all but 0.9 kilograms of prior weight loss. Zepbound switchers regained about five kilograms.

With VK2735, Viking offers a third option: a monthly shot. For patients who dislike daily pills or weekly needles, that's a real convenience. Better adherence is what makes weight loss durable. Payers may also like a lower-dose maintenance regimen if it lowers cost per patient.

However, Viking is likely to have competition sooner rather than later. Amgen NYSE: AMGN has MariTide and Pfizer NYSE: PFE with berobenatide, acquired through Metsera, are both pursuing monthly dosing. While monthly dosing is a differentiator today, it may be table stakes by the time VK2735 reaches the market.

What Phase 3 Still Has to Prove

The maintenance study was short and small. A 12-week trial says little about what happens after a year or more. It also enrolled otherwise healthy adults, not the higher-risk patients who drive much of the market.

The VANQUISH Phase 3 program addresses some of that. VANQUISH-1 enrolled about 4,500 adults with obesity. VANQUISH-2 enrolled about 1,000 with obesity and type 2 diabetes. Both are 78-week trials, with readouts expected in 2027.

But VANQUISH tests weekly dosing. Maintenance regimens will be studied in extension trials expected to start in late 2026 or early 2027. Viking also plans to begin an oral Phase 3 program this quarter.

How Does Viking Pay for the Road to Approval?

Viking ended June with about $502 million in cash. Management says that funds operations into 2028. That should cover the VANQUISH readouts. It likely won't cover a full commercial launch.

Building manufacturing and a sales force to take on Lilly and Novo is expensive. Viking has three realistic paths. It can raise equity, thereby diluting shareholders. It can partner with a larger drugmaker. Or it can be acquired.

Takeover talk has followed Viking for years. Pfizer's roughly $10 billion Metsera deal, won in a bidding war with Novo, shows big pharma's appetite for obesity assets. But that's a scenario, not a prediction. Viking has so far advanced VK2735 on its own.

VKTX Stock Technical Analysis: Can the Rally Break $43?

Analyst sentiment for VKTX remains strong. The consensus price target of $99.22 offers upside of 150%. However, context is important. That price target was in place before the latest results of VK2735.

Analysts understand that it will still be some time before the Phase 3 study is completed, and even longer before the drug gains commercial approval.

The chart confirms that cautious story. VKTX gapped up from around $30 to over $40 on the news. Volume was the highest in the past year, confirming real buying interest. The stock also reclaimed its 50-day simple moving average (SMA), now near $34.

But the rally is running into a familiar ceiling. The $42.50 to $43 zone capped the stock in November 2025 and again in July. On Sept. 23, shares touched $42.92 before reversing lower.

Momentum is cooling as well. The relative strength index (RSI) neared overbought territory at 70 and eased to around 65. The 50-day SMA is also still sloping down. A pullback toward the $34 to $37 range would not be surprising. A close above $43 would signal a true breakout.

Viking Stock: A GLP-1 Durability Play, Not a Zepbound Rival

The GLP-1 trade has matured. Being "another obesity drug" is no longer enough to win investor dollars. Viking's maintenance data points to a different identity: the durability and convenience option.

Whether that identity holds depends on Phase 3 and on how fast monthly rivals move. For now, the rally reflects a narrative shift more than a proven commercial edge. Investors should price it accordingly.